A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Name: A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Published: 2021
License: Public Domain

Bristol-Myers Squibb · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

conversion egfr

renal allograft recipients, acute rejection, belatacept, calcineurin inhibitors (cyclosporine, tacrolimus), conversion, donor-specific antibodies, egfr, immunosuppressive regimen, adolescent kidney transplant recipients, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents